Nanobiotix vs Pyxis Oncology
NBTX and PYXS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NBTX and PYXS compare
Pyxis Oncology scores higher on the StockData Score (5 against 3 for Nanobiotix), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NBTX | PYXS |
|---|---|---|
| Size and price | ||
| Market cap | – | $132M |
| Share price | $30.66 | $1.58 |
| Change, 1 year | 42.1% | −63.8% |
| Change, 5 years | 231% | −87.8% |
| Beta (5Y) | 0.47 | 1.61 |
| Employees | 97 | 56 |
| StockData Score | ||
| Total score | 3 | 5 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | – | 3.2× |
| Growth | ||
| Revenue growth, 5Y average | 67.0% | – |
| Profitability | ||
| Operating margin | −33.2% | – |
| Net margin | −73.5% | – |
| FCF margin | −104% | – |
| Return on equity | – | −158% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −0.7× | – |
| Current ratio | 1.44 | 2.96 (better) |
| Altman Z-score | – | −10.32 |
| Piotroski F-score | 4 (better) | 1 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 12.0% | 40.9% |
| Held by insiders | 0.00% | 20.4% |
| Insider net buying, 12 months | – | −$107K |
| Short interest, % of float | – | 6.8% |
Go deeper
- NBTX stock overview
- NBTX income statement
- NBTX valuation and score
- PYXS stock overview
- PYXS income statement
- PYXS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.